Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study

Eun Soo Kim; Chung Hyun Tae; Sung-Ae Jung; Dong Il Park; Jong Pil Im; Chang Soo Eun; Hyuk Yoon; Byung Ik Jang; Haruhiko Ogata; Kayoko Fukuhara; Fumihito Hirai; Kazuo Ohtsuka; Jing Liu; Qian Cao

doi:10.5217/ir.2020.00150

Articles

Page Path: HOME > Intest Res > Volume 20(2); 2022 > Article

Original Article Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study: Eun Soo Kim¹, Chung Hyun Tae², Sung-Ae Jung², Dong Il Park³, Jong Pil Im⁴, Chang Soo Eun⁵, Hyuk Yoon⁶, Byung Ik Jang⁷, Haruhiko Ogata^8,, Kayoko Fukuhara⁸, Fumihito Hirai⁹, Kazuo Ohtsuka¹⁰, Jing Liu¹¹, Qian Cao¹²; Intestinal Research 2022;20(2):192-202.
DOI: https://doi.org/10.5217/ir.2020.00150
Published online: April 29, 2022

¹Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea

²Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea

³Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea

⁴Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

⁵Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea

⁶Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

⁷Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea

⁸Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

⁹Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital, Chikushino, Japan

¹⁰Endoscopic Unit, Tokyo Medical and Dental University Hospital, Tokyo, Japan

¹¹Department of Internal Medicine, Peking Union Medical College Hospital, Beijing, China

¹²Gastroenterology Department, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine, Zhejiang, China

Correspondence to Haruhiko Ogata, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Tel: +81-3-3353-1211, Fax: +81-3353-3536, E-mail: hogata@z8.keio.jp

• Received: November 24, 2020 • Revised: January 6, 2021 • Accepted: March 12, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

3,643 Views
161 Download
2 Web of Science
2 Crossref
2 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Supplementary Material
REFERENCES

Abstract

Background/Aims
Complementary and alternative medicine (CAM) is prevalent in East Asia. However, information on CAM in East Asian patients with inflammatory bowel disease (IBD) is scarce. We aimed to profile the prevalence and pattern of CAM use among East Asian IBD patients and to identify factors associated with CAM use. We also compared physicians’ perspectives on CAM.
Methods
Patients with IBD from China, Japan, and South Korea were invited to complete questionnaires on CAM use. Patient demographic and clinical data were collected. Logistic regression analysis was applied for predictors of CAM use. Physicians from each country were asked about their opinion on CAM services or products.
Results
Overall, 905 patients with IBD participated in this study (China 232, Japan 255, and South Korea 418). Approximately 8.6% of patients with IBD used CAM services for their disease, while 29.7% of patients sought at least 1 kind of CAM product. Current active disease and Chinese or South Korean nationality over Japanese were independent predictors of CAM use. Chinese doctors were more likely to consider CAM helpful for patients with IBD than were Japanese and South Korean doctors.
Conclusions
In 8.6% and 29.7% of East Asian patients with IBD used CAM services and products, respectively, which does not differ from the prevalence in their Western counterparts. There is a significant gap regarding CAM usage among different Asian countries, not only from the patients’ perspective but also from the physicians’ point of view.
Keywords: Complementary and alternative medicine; Inflammatory bowel disease; East Asia

INTRODUCTION

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a disabling and chronic relapsing inflammatory condition of the bowel. Without optimal treatment, it may cause irreversible bowel damage and lead to a negative impact on patients’ quality of life. Although IBD is the most prevalent disease in Western countries, the incidence of the disease has been rapidly increasing in East Asia, making it a global disease [1].

The cause of IBD is unknown, and there is no absolute cure. Although several therapeutic advances have been made in recent years, the unsatisfactory response rate, increased risk of relapse over time and adverse effects of therapy remain unmet clinical needs for the conventional management of IBD [2,3]. For instance, up to 40% of patients show primary or secondary nonresponse to biologic therapy targeting tumor necrosis factor (TNF), which has been regarded as the most effective treatment of IBD [4]. These limitations of current treatment may drive patients’ interest in complementary and alternative medicine (CAM).

CAM is defined as a group of diverse medical and health care systems, practices, and products that are not presently considered part of conventional medicine [5]. Patients with chronic diseases such as IBD seek CAM amid concerns of response failure or side effects of standard therapy [6,7]. The use of CAM by patients with IBD is remarkably high [8,9]. Meanwhile, doctors do not seem to be prepared to address CAM-related issues among their patients. A third of physicians are not comfortable discussing CAM with their IBD patients due to a lack of knowledge [10]. Medical care providers need to be aware of patients’ intentions to use CAM because CAM may have negative impacts on the care of IBD. First, it may negatively influence doctor-patient relationships, since CAM use reflects dissatisfaction with the current standard therapy [11]. Second, there might be a potential critical interaction between current therapy and CAM [12]. Third, CAM use is reported to be associated with poor compliance in patients [8].

With the substantial popularity and acceptance of CAM in the general population, the prevalence of CAM use differs by country because of various economic, social and cultural factors. CAM use is considered to be widespread in East Asia because traditional oriental medicine, which is one of the main streams of CAM, originated in this area [13]. In a systematic review exploring CAM use by the general population in 15 countries, the 12-month prevalence of CAM use varied widely from 9.8% to 76% [14]. Among these countries, the highest rates of CAM use were observed in East Asian countries, including Japan (76%), South Korea (75%), and Singapore (76%). However, the prevalence and pattern of CAM use in patients with IBD from these areas have not been fully evaluated or compared. In addition, IBD doctors’ perspectives on CAM are unknown in this area. We aimed to evaluate and compare the prevalence of CAM use in patients with IBD in China, Japan, and South Korea. Furthermore, we asked physicians for their opinions on CAM for patients with IBD.

METHODS

1. Study Design

This was a cross-sectional, multinational study conducted in China, Japan, and South Korea from November 2017 to March 2018. Patients diagnosed with IBD for at least 6 months in tertiary hospitals were eligible for the study. IBD diagnosis was made based on a detailed history, physical examination, and combination of endoscopic features, histology, radiographic findings, and laboratory investigations. Participants who were younger than 18 years old or who were not able to read questionnaires were excluded. On an outpatient basis, they were consecutively invited to complete a questionnaire on CAM use over the past 12 months. Patient demographic and clinical data were collected. Regarding physicians’ perspectives on CAM, we invited doctors to participate in the study using the network in the Clinical Research Committee of the Asian Organization for Crohn’s and Colitis. We asked them to report on whether CAM is beneficial or recommendable for their IBD patients. Questionnaires used in the study are provided as Supplementary Material. This study was approved by the institutional review board of all participating hospitals (IRB No. KNUH2017-09-007-004). Written informed consent was obtained.

2. Data Collection

Patient demographic data, such as age, comorbidities, and sex, were collected. comorbidities included hypertension, diabetes mellitus, renal disease, respiratory disease, atopy, and malignancy. Clinical data included disease duration, disease activity, current medication, previous IBD-related hospitalization, and surgery history. The disease activity of CD and UC was assessed by the Harvey-Bradshaw index (HBI) and the Simple Clinical Colitis Activity Index (SCCAI), respectively. Scores equal to or more than 5 reflected active disease on both the HBI and SCCAI [15,16]. For physicians, data on age, sex, practice type (such as primary or referral center), and specialty (including IBD specialist, general gastrointestinal physician, pediatrician, and surgeon) were collected.

3. CAM Assessment

CAM was categorized into services and products; services in the study included massage, acupuncture, naturopathic medicine, homoeopathy, relaxation, reflexology, aromatherapy, hypnosis, moxibustion or cupping, spiritual or religious healing, and chiropractic therapy, whereas products in the study included herbal remedies, ginseng, deer antler, Chinese medicine, St. John’s wort, chamomile, lavender, ginkgo biloba, kava kava, vitamins, probiotics, fish oils, and glucosamine [9]. At first, patients were asked whether they used CAM services or products in general during the last year. Then, if they used CAM, they were asked whether it was specifically related to IBD.

4. Statistical Analysis

The sample size was calculated on the assumption that there will be a 15% difference in the prevalence of CAM use between countries (60% vs. 45%). With a 20% withdrawal rate and 80% power to detect such a difference at a two-tailed significance level of 0.05, at least 220 patients from each country were required.

Differences in categorical data among groups were examined by using chi-square or Fisher exact test. For continuous variables among 3 countries, analysis of variance was used. The pairwise Wilcoxon rank-sum test was used for multiple measurements of the nonparametric data among groups. The prevalence of CAM was compared among countries with adjustment of confounders such as age, duration of disease, sex, comorbidities, disease activity, current medications and previous history of surgery and admission. Independent factors associated with CAM use were analyzed by logistic regression. Variables with P-values less than 0.05 were selected for multivariate analysis. Multiple comparisons were corrected using the Bonferroni method. All tests were two-sided, and a P-value < 0.05 indicated statistical significance. All statistical analyses were performed using R package version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

1. Baseline Characteristics of Patients

Fifteen institutions from 3 countries participated (China 5, Japan 3, and Korea 7), and 905 IBD patients were enrolled in the study (China 232, Japan 255, and South Korea 418). There was a significant difference in baseline characteristics among 3 countries (Table 1). Japanese patients were older (mean ± standard deviation [SD]: China 38.8 ± 14.2 years vs. Japan 43.2 ± 13.7 years vs. Korea 40.8 ± 15.3 years, P= 0.001) and had longer disease duration (mean ± SD: China 4.1 ± 4.4 years vs. Japan 10.8 ± 8.2 years vs. Korea 7.0 ± 6.2 years, P< 0.001) with higher rate of comorbidities (China 17.2% vs. Japan 45.1% vs. Korea 29.7%, P< 0.001) than patients from other countries. Chinese patients were more likely to have an active disease at enrollment (China 47.0% vs. Japan 18.0% vs. Korea 12.7%, P< 0.001) which was in line with higher rate of current steroid use (China 23.3% vs. Japan 10.2% vs. Korea 9.6%, P< 0.001) than patients from other countries. Tacrolimus was only used in Japanese patients with UC (3.1%, P< 0.001) while anti-TNF was more often used in South Korean patients (China 22.1% vs. Japan 23.1% vs. Korea 30.9%, P= 0.018). Previous surgery (China 22.4% vs. Japan 9.0% vs. Korea 18.2%, P< 0.001) and hospital admission related to IBD (China 95.7% vs. Japan 35.3% vs. Korea 49.9%, P< 0.001) were most observed in Chinese patients.

2. Prevalence of CAM Services and Product Use

Korean patients with IBD were generally more likely to use CAM services (P< 0.001) or products (P< 0.001) than were Chinese or Japanese patients (Supplementary Table 1). However, Chinese patients were more likely to use CAM products for the purpose of managing IBD (P< 0.001) (Supplementary Table 1). Up to 8.6% of patients with IBD consumed CAM services for the management of IBD during the last year, with no significant difference among nations (China 8.6% vs. Japan 5.1% vs. Korea 10.8%, P= 0.179) (Table 2). However, there was a significant difference in multiple service users ( ≥ 2 services) among nations (China 3.4% vs. Japan 0% vs. Korea 3.3%, P= 0.027). There was no difference in the use of each CAM service among patients with CD by country, except chiropractic service which was more utilized by Chinese patients (China 3% vs. Japan 0.4% vs. Korea 0.5%, P= 0.047). Among various CAM services, moxibustion/cupping was the most common service used by IBD patients (2.9%).

For CAM products, 29.7% of East Asian patients with IBD used at least 1 type of CAM product for the management of IBD during the last year with Chinese patients being the most common user (China 50.4% vs. Japan 12.5% vs. Korea 28.7%, P< 0.001). There was a significant difference in multiple product users ( ≥ 2 products) among nations (China 30.2% vs. Japan 3.1% vs. Korea 12.4%, P< 0.001). Chinese patients were more likely to use herbal remedies (P= 0.002), Chinese medicine (P< 0.001), vitamins (P< 0.001), probiotics (P< 0.001) and glucosamine (P< 0.001) than Japanese or Korean patients (Table 3). Probiotics was the most frequently used product (19.3%). Those comparisons of prevalence were conducted with the adjustment of age, duration of disease, sex, comorbidities, disease activity, current medications and previous history of surgery and admission related to IBD.

3. Predictive Factors of CAM Use

In univariate analysis, Chinese or Korean nationality (P= 0.04), active disease (P= 0.003), and anti-TNF use (P= 0.031) were significantly associated with CAM service use. Among them, multivariate analysis found South Korean nationality over Japanese (odds ratio [OR], 2.31; 95% confidence interval [CI], 1.21–4.41; P= 0.011) and active disease status (OR, 2.46; 95% CI, 1.45–4.19; P= 0.001) to be independent predictors of the use of CAM services. Younger age (P= 0.035), less comorbidities (P= 0.012), Chinese or Korean nationality (P< 0.001), active disease (P< 0.001), steroid use (P= 0.018) and previous admission related to IBD (P< 0.001) were significantly associated with CAM product use. Among them, Chinese (OR, 5.15; 95% CI, 3.1–8.58; P< 0.001) and South Korean nationality over Japanese (OR, 2.73; 95% CI, 1.77–4.22; P< 0.001) and active disease status (OR, 1.45; 95% CI, 1.01–2.08; P= 0.043) were found to be independent predictors of CAM product consumption in the multivariate analysis (Table 4).

4. Physicians’ Perception of CAM Usage for Their IBD Patients

Physicians were recruited for surveys from China (n = 20), Japan (n = 104), and South Korea (n = 29). The characteristics of these physicians are described in Supplementary Table 2. Chinese doctors were significantly younger (P= 0.003) and were predominantly female (P< 0.001) compared to doctors from other countries. More Japanese doctors worked at primary clinics than Chinese and South Korean doctors (P= 0.01). Therefore, these 3 factors (age, sex, and practice hospital) were adjusted in further comparisons among the 3 countries. Relaxation and probiotics were most frequently considered beneficial/recommendable services and products, respectively, by overall physicians. For CAM services, more Chinese physicians thought that acupuncture, naturopathic medicine, hypnosis, moxibustion/cupping, and spiritual healers were helpful, while more Japanese physicians regarded reflexology as an effective service for their IBD patients (Fig. 1A). For CAM products, Chinese doctors were more likely to consider herbal remedies, Chinese medicine, and glucosamine as beneficial/recommendable for their patients with IBD than were Japanese and South Korean doctors (Fig. 1B). Chinese and South Korean doctors regarded vitamins as helpful CAM for IBD compared with Japanese doctors (Fig. 1B).

Then, we tried to determine whether there was a difference regarding overall perceptions toward CAM among physician groups by measuring the median number of beneficial/recommendable forms of CAM considered by physicians from each country. Chinese doctors had a significantly higher median number (interquartile range) of beneficial/recommendable CAM services (China 2 [1–4] vs. Japan 1 [0–3] vs. Korea 1 [0–2]) or products (China 3 [3–5] vs. Japan 2 [1–3] vs. Korea 3 [2–3]) than did doctors from the other 2 countries, while there was no difference between Japanese and South Korean doctors (Fig. 2).

DISCUSSION

This cross-sectional, multinational study demonstrated that approximately 1 in 10 and 1 in 3 East Asian patients with IBD used CAM services and products, respectively, for the management of IBD during the past year. Moxibustion/cupping was the most used CAM service by patients (2.9%) (Table 2), while most physicians considered relaxation to be a helpful CAM service for IBD (58%) (Fig. 1A). Probiotics were the most frequently consumed CAM products by patients (19.3%) (Table 3) and were also thought to be effective CAM products by most physicians (86%) (Fig. 1B). Chinese or South Korean patients over Japanese and current disease activity were independent predictors of CAM use for IBD management. In addition, Chinese doctors were more likely to perceive that CAM was helpful for IBD than were Japanese and Korean doctors (Fig. 2). To the best of our knowledge, this is the first report to compare the perspectives on CAM use among IBD patients from different East Asian countries as well as among physicians.

CAM use is highly prevalent among patients with IBD. In the studies reporting current or past CAM use together, the prevalence spanned a wide range (21%–77%) among patients with IBD [8,9,17-20]. Most studies in Western countries, such as North America and Northern Europe, exhibited a high prevalence of CAM use of 44% to 77% [8,9,18,21,22], which is higher than the prevalence in our study and in East Asian countries. Korean studies showed 28% to 38% prevalence in Korean IBD patients [23,24]. Chinese patients with IBD in Hong Kong also had a low prevalence of 33% compared with their Western counterparts [25]. However, caution should be taken when comparing the rate of usage among studies due to heterogeneous study designs and methodologies. For instance, there is a difference in the purpose of CAM use in patients with IBD. They may seek CAM for their IBD or for other health issues, including their general well-being. A survey-based study with 392 Canadian patients with IBD showed a prevalence rate of 62% for overall CAM usage, of which only one-third used CAM for IBD management similar with our result [8]. Another Western study [9,17] also reported that only 18% to 21% of IBD patients consumed CAM for their IBD, which is consistent with our results. In the present study, the prevalence of CAM service use was reduced to 8.6% for IBD management from 36.2% for overall indications, and the prevalence of CAM product use was reduced to 29.7% for IBD management from 60.2% for overall indications (Supplementary Table 1). As many patients use CAM for purposes other than IBD management, they may not report CAM use to their doctors. Therefore, this finding underscores the fact that doctors should actively engage in a discussion of CAM use with their IBD patients because CAM may cause a potential risk of drug interactions or liver toxicity [12,26,27].

We found a significant difference regarding perceptions of CAM use among patients in different countries; Chinese and South Korean patients are more likely to utilize CAM for IBD than are Japanese patients (Table 4). Despite uncertainty, this difference might be attributed to the unique health care system of traditional oriental medicine, which mainly accounts for the CAM services or products in each country. For instance, China and South Korea have a similar pattern of national policies and resources and a formal educational system of traditional medicine [28]. These 2 countries include traditional medicine in the national health care system and have their own educational course for doctors specializing in traditional medicine, whose position is defined by the law and regulated by the government, probably resulting in a high level of social acceptance of CAM in the general population. In contrast, Japan has no formal system of traditional medicine; only herbal mixtures known as Kampo and some acupuncture are included in the health care system [28]. Furthermore, no official educational system exists specific to traditional medicine in Japan [28]. This might suggest that varied historical and cultural background might explain the disparity of perception among countries. The different accessibility to CAM use in each country would be another reason for the different perception among countries.

Intriguingly, there was a gap in the perception of CAM between South Korean patients with IBD and doctors; South Korean patients favored CAM (Table 4), whereas South Korean doctors were less likely to think CAM was an effective method of addressing IBD (Fig. 2). Although we could not explain this disparity in perceptions between patients and doctors in South Korea, this finding suggests a possible greater risk of poor doctor-patient relationships with respect to CAM use in South Korea. However, a recent study showed that more Korean patients with IBD have negative attitudes toward CAM use regarding its effectiveness compared to a decade ago probably due to reliable information from the internet, advent of social media and activation of on-and-offline IBD communities in the recent years [24].

Apart from the nationality of patients, we identified current active disease as another independent predictor of CAM use, which is consistent with the results of previous study [7]. This finding indicates that sicker patients with IBD are more likely to use CAM.

Of note, relaxation was considered a helpful form of CAM for IBD by most physicians, which is in line with the position statement of the European Crohn’s and Colitis Organization [29]. Several studies have shown that relaxation reduces symptoms and improves quality of life in patients with IBD [30,31]. However, we found that moxibustion/cupping was the most frequently used CAM service by patients, which is not supported by the literature [29]. Furthermore, although probiotics were the most used CAM by patients and were considered a beneficial/recommendable form of CAM by most doctors in our study, growing evidence does not support the role of probiotics in the management of IBD; only specific strains seem to be effective in UC [29]. Hence, adequate education guided by evidence is necessary for IBD patients to use CAM optimally.

We acknowledged the failure to obtain information on education level, socio-economic status such as income, insurance system and adherence to IBD treatment of patients from each country as the main limitation of the study because these variables are known to influence CAM usage [18,23,32]. In addition, different educational background or system of the medical school in each country, which was not assessed in the study, might influence doctors’ perspectives. Different age of doctors might also affect their attitude to CAM use as young and senior physicians may have different levels of exposure to CAM.

In summary, this study demonstrated that the prevalence of CAM use for IBD in East Asian countries does not differ from the prevalence in their Western counterparts (8.6% for CAM services and 29.7% for CAM products). We found that there was a significant gap with respect to CAM usage among different East Asian countries, not only from the patients’ perspective but also from the physicians’ point of view. This disparity might be attributed to the different historical and cultural backgrounds of traditional medicine in each country.

NOTES

Funding Source

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

Park DI is an editorial board member of the journal but was not involve in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Author Contribution

Study concept, design, analysis of data: Kim ES. Study concept, design: Ogata H. Substantial contribution to the acquisition and interpretation of data for the work: Tae CH, Jung SA, Park DI, Im JP, Eun CS, Yoon H, Jang BI, Fukuhara K, Hirai F, Ohtsuka K, Liu J, Cao Q. Drafting of the manuscript: Kim ES. Critical revision of the manuscript: Ogata H. Approval of final manuscript: all authors.

Supplementary Material

Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

Supplementary Table 1. Prevalence of CAM Use According to Different Indications Among Patients with IBD from 3 Countries

ir-2020-00150-suppl1.pdf

Supplementary Table 2. Characteristics of Physicians from 3 Countries

ir-2020-00150-suppl2.pdf

Supplementary Material. Questionnaire

ir-2020-00150-suppl3.pdf

Fig. 1.

The prevalence of complementary and alternative medicine service (A) and product (B) usage among patients with inflammatory bowel disease from 3 countries. The P-value is for the analysis of variance and was adjusted for physicians’ age and sex and the hospital type. ^aP<0.05, ^bP<0.01, ^cP<0.001.

Fig. 2.

Comparison of physicians’ perspectives on complementary and alternative medicine (CAM) services (A) and products (B) for inflammatory bowel disease among 3 countries. The width of the box indicates the sample size of participants from each country. The P-value was calculated using the pairwise Wilcoxon rank-sum test after adjustment for physicians’ age and sex and the hospital type. ^aP<0.05, ^bP<0.001. NS, not significant.

Table 1.

Baseline Characteristics of Patients in the Study

Characteristics	China (n = 232)	Japan (n = 255)	Korea (n = 418)	P-value
Age at enrollment (yr)	38.8 ± 14.2	43.2 ± 13.7	40.8 ± 15.3	0.001
Disease duration (yr)	4.1 ± 4.4	10.8 ± 8.2	7.0 ± 6.2	< 0.001
Male sex	143 (61.6)	129 (50.6)	269 (64.5)	0.001
Comorbidities	40 (17.2)	115 (45.1)	124 (29.7)	< 0.001
SCCAI	5.1 ± 4.2	0.7 ± 1.5	1.9 ± 2.1	< 0.001
HBI score	3.8 ± 2.5	2.3 ± 2.6	2.3 ± 2.3	< 0.001
Active disease at enrollment	109 (47.0)	46 (18.0)	53 (12.7)	< 0.001
Current medications
Steroid	54 (23.3)	26 (10.2)	40 (9.6)	< 0.001
Thiopurine	45 (19.4)	106 (41.6)	135 (32.4)	< 0.001
Tacrolimus	0	8 (3.1)	0	< 0.001
Anti-TNFs	51 (22.1)	59 (23.1)	129 (30.9)	0.018
Previous surgery related with IBD	52 (22.4)	23 (9.0)	76 (18.2)	< 0.001
Previous admission related with IBD	222 (95.7)	90 (35.3)	208 (49.9)	< 0.001

Values are presented as mean±standard deviation or number (%). Active disease was defined as HBI ≥5 for Crohn’s disease and SCCAI ≥5 for ulcerative colitis.

SCCAI, Simple Clinical Colitis Activity Index; HBI, Harvey-Bradshaw index; TNF, tumor necrosis factor; IBD, inflammatory bowel disease.

Table 2.

Prevalence of Complementary and Alternative Medical Services Usage in Inflammatory Bowel Disease Patients According to Countries

Variable	China (n = 232)	Japan (n = 255)	Korea (n = 418)	Total (n = 905)	P-value^a
Massage	5 (2.2)	2 (0.8)	4 (1.0)	11 (1.2)	0.166
Acupuncture	5 (2.2)	2 (0.8)	16 (3.8)	23 (2.5)	0.995
Naturopathic medicine	4 (1.7)	1 (0.4)	1 (0.2)	6 (0.6)	0.195
Homoeopathy	2 (0.9)	0	7 (1.7)	9 (0.9)	0.898
Relaxation	6 (2.6)	2 (0.8)	2 (0.5)	10 (1.1)	0.626
Reflexology	0	4 (1.6)	5 (1.2)	9 (0.9)	0.871
Aromatherapy	0	0	0	0	NA
Hypnosis	0	0	0	0	NA
Moxibustion or cupping	8 (3.4)	0	19 (4.5)	27 (2.9)	0.051
Spiritual or religious healer	3 (1.3)	0	1 (0.2)	4 (0.4)	0.108
Chiropractic	7 (3.0)	1 (0.4)	2 (0.5)	10 (1.1)	0.047
CAM ≥ 2 services	8 (3.4)	0	14 (3.3)	22 (2.4)	0.027
Any CAM service	20 (8.6)	13 (5.1)	45 (10.8)	78 (8.6)	0.179

Values are presented as number (%).

^a The comparison was adjusted with age, duration of disease, sex, comorbidities, disease activity, current medications and previous history of surgery and admission.

CAM, complementary and alternative medicine; NA, not applicable.

Table 3.

Prevalence of Complementary and Alternative Medical Products Usage in Inflammatory Bowel Disease Patients According to Countries

Variable	China (n = 232)	Japan (n = 255)	Korea (n = 418)	Total (n = 905)	P-value^a
Herbal remedies	22 (9.5)	4 (1.6)	13 (3.1)	39 (4.3)	0.002
Ginseng	1 (0.4)	0	14 (3.3)	15 (1.6)	0.814
Deer antlers	0	0	2 (0.5)	2 (0.2)	0.368
Chinese medicine (drugs)	29 (12.5)	5 (2)	33 (7.9)	67 (7.4)	< 0.001
St. John’s wort	0	0	0	0	NA
Chamomile	1 (0.4)	1 (0.4)	4 (1.0)	6 (0.6)	0.502
Lavender	0	0	1 (0.2)	1 (0.1)	0.486
Ginkgo biloba	0	0	0	0	NA
Kava kava	0	0	0	0	NA
Vitamins	70 (30.2)	2 (0.8)	36 (8.6)	108 (11.9)	< 0.001
Probiotics	81 (34.9)	19 (7.5)	75 (17.9)	175 (19.3)	< 0.001
Fish oils	1 (0.4)	3 (1.2)	5 (1.2)	9 (0.9)	0.505
Glucosamine	19 (8.2)	0	5 (1.2)	24 (2.6)	< 0.001
CAM ≥ 2 products	70 (30.2)	8 (3.1)	52 (12.4)	130 (14.3)	< 0.001
Any product	117 (50.4)	32 (12.5)	120 (28.7)	269 (29.7)	< 0.001

Values are presented as number (%).

^a The comparison was adjusted with age, duration of disease, sex, comorbidities, disease activity, current medications and previous history of surgery and admission.

CAM, complementary and alternative medicine; NA, not applicable.

Table 4.

Associated Factors with Complementary and Alternative Medicine in Patients with IBD

Factor	CAM service					CAM product
	Univariate analysis			Multivariate analysis		Univariate analysis			Multivariate analysis
	User (n=78)	Nonuser (n=827)	P-value	OR (95% CI)	P-value	User (n=269)	Nonuser (n=636)	P-value	OR (95% CI)	P-value
Age at enrollment (yr)	39.54 ± 13.43	41.09 ± 14.74	0.370			39.39 ± 13.97	41.62 ± 14.87	0.035	0.99 (0.98–1.00)	0.321
Disease duration (yr)	7.34 ± 5.86	7.29 ± 6.94	0.955			6.65 ± 6.33	7.57 ± 7.10	0.068
Male sex	46 (59.0)	495 (59.9)	0.904			158 (58.7)	383 (60.3)	0.657
Comorbidities	25 (32.1)	254 (30.7)	0.799			67 (24.9)	212 (33.3)	0.012	0.91 (0.64–1.29)	0.578
Disease			0.808					0.940
CD	31 (39.7)	314 (38)				103 (38.3)	242 (38.1)
UC	47 (60.3)	513 (62)				166 (61.7)	394 (61.9)
Countries			0.040					< 0.001
China	20 (25.6)	212 (25.6)		1.35 (0.64–2.86)	0.428	117 (43.5)	115 (18.1)		5.15 (3.10–8.58)	< 0.001
Japan	13 (16.7)	242 (29.3)		1 (reference)		32 (11.9)	223 (35.1)		1 (reference)
Korea	45 (57.7)	373 (45.1)		2.31 (1.21–4.41)	0.011	120 (44.6)	298 (46.9)		2.73 (1.77–4.22)	< 0.001
Active disease	29 (37.2)	180 (21.8)	0.003	2.46 (1.45–4.19)	0.001	87 (32.3)	122 (19.2)	< 0.001	1.45 (1.01–2.08)	0.043
Steroid	10 (12.8)	110 (13.3)	0.946			47 (17.5)	73 (11.5)	0.018	1.27 (0.83–1.96)	0.273
Thiopurine	24 (30.8)	262 (31.7)	0.899			81 (30.1)	205 (32.3)	0.533
Anti-TNFs	29 (37.2)	210 (25.5)	0.031	1.59 (0.96–2.60)	0.068	68 (25.4)	171 (26.9)	0.680
Previous surgery related with IBD	14 (18.2)	137 (16.6)	0.749			51 (19.0)	100 (15.7)	0.243
Previous admission related with IBD	47 (61.0)	473 (57.2)	0.548			192 (71.4)	328 (51.7)	< 0.001	1.28 (0.89–1.85)	0.121

Values are presented as mean±standard deviation or number (%). Active disease was defined as Harvey-Bradshaw index ≥5 for CD and Simple Clinical Colitis Activity Index ≥5 for UC.

IBD, inflammatory bowel disease; CAM, complementary and alternative medicine; OR, odds ratio; CI, confidence interval; CD, Crohn’s disease; UC, ulcerative colitis; TNF, tumor necrosis factor.

REFERENCES

1. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017;152:313–321.Article PubMed
2. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929–936.Article PubMed
3. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximaband immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1051–1063.Article PubMed PMC PDF
4. Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis 2015;21:182–197.PubMed
5. Cheifetz AS, Gianotti R, Luber R, Gibson PR. Complementary and alternative medicines used by patients with inflammatory bowel diseases. Gastroenterology 2017;152:415–429.Article PubMed
6. Hilsden RJ, Verhoef MJ, Best A, Pocobelli G. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol 2003;98:1563–1568.Article PubMed
7. Li FX, Verhoef MJ, Best A, Otley A, Hilsden RJ. Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey. Can J Gastroenterol 2005;19:567–573.Article PubMed PDF
8. Nguyen GC, Croitoru K, Silverberg MS, Steinhart AH, Weizman AV. Use of complementary and alternative medicine for inflammatory bowel disease is associated with worse adherence to conventional therapy: the COMPLIANT Study. Inflamm Bowel Dis 2016;22:1412–1417.PubMed
9. Rawsthorne P, Clara I, Graff LA, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products. Gut 2012;61:521–527.Article PubMed
10. Gallinger ZR, Nguyen GC. Practices and attitudes toward complementary and alternative medicine in inflammatory bowel disease: a survey of gastroenterologists. J Complement Integr Med 2014;11:297–303.Article PubMed
11. Hung A, Kang N, Bollom A, Wolf JL, Lembo A. Complementary and alternative medicine use is prevalent among patients with gastrointestinal diseases. Dig Dis Sci 2015;60:1883–1888.Article PubMed PDF
12. Mannel M. Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf 2004;27:773–797.PubMed
13. Cheung F. TCM: made in China. Nature 2011;480:S82–S83.Article PubMed PDF
14. Harris PE, Cooper KL, Relton C, Thomas KJ. Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. Int J Clin Pract 2012;66:924–939.Article PubMed
15. Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Defining relapse of ulcerative colitis using a symptombased activity index. Scand J Gastroenterol 2003;38:164–171.Article PubMed
16. Best WR. Predicting the Crohn’s disease activity index from the Harvey-Bradshaw index. Inflamm Bowel Dis 2006;12:304–310.Article PubMed
17. Bensoussan M, Jovenin N, Garcia B, et al. Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey. Gastroenterol Clin Biol 2006;30:14–23.PubMed
18. Weizman AV, Ahn E, Thanabalan R, et al. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:342–349.Article PubMed
19. Portela F, Dias CC, Caldeira P, et al. The who-when-why triangle of CAM use among Portuguese IBD patients. Dig Liver Dis 2017;49:388–396.PubMed
20. Abitbol V, Lahmek P, Buisson A, et al. Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease: results from a French national survey. Eur J Gastroenterol Hepatol 2014;26:288–294.PubMed
21. Joos S, Rosemann T, Szecsenyi J, Hahn EG, Willich SN, Brinkhaus B. Use of complementary and alternative medicine in Germany: a survey of patients with inflammatory bowel disease. BMC Complement Altern Med 2006;6:19.Article PubMed PMC PDF
22. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: perceived stress is a potential indicator for CAM use. Complement Ther Med 2007;15:30–37.Article PubMed
23. Park DI, Cha JM, Kim HS, et al. Predictive factors of complementary and alternative medicine use for patients with inflammatory bowel disease in Korea. Complement Ther Med 2014;22:87–93.Article PubMed
24. Lee SH, Chang K, Seo KS, et al. Changes in prevalence and perception of complementary and alternative medicine use in Korean inflammatory bowel disease patients: results of an 8-year follow-up survey. Intest Res 2020;18:192–199.Article PubMed PMC PDF
25. Leong RW, Lawrance IC, Ching JY, et al. Knowledge, quality of life, and use of complementary and alternative medicine and therapies in inflammatory bowel disease: a comparison of Chinese and Caucasian patients. Dig Dis Sci 2004;49:1672–1676.Article PubMed
26. Stadlbauer V, Fickert P, Lackner C, et al. Hepatotoxicity of NONI juice: report of two cases. World J Gastroenterol 2005;11:4758–4760.Article PubMed PMC
27. Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 2003;18:451–471.Article PubMed PDF
28. Park HL, Lee HS, Shin BC, et al. Traditional medicine in china, Korea, and Japan: a brief introduction and comparison. Evid Based Complement Alternat Med 2012;2012:429103.Article PubMed PMC PDF
29. Torres J, Ellul P, Langhorst J, et al. European Crohn’s and Colitis Organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease. J Crohns Colitis 2019;13:673–685e.Article PubMed PDF
30. Langhorst J, Wulfert H, Lauche R, et al. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis 2015;9:86–106.Article PubMed
31. Norton C, Czuber-Dochan W, Artom M, Sweeney L, Hart A. Systematic review: interventions for abdominal pain management in inflammatory bowel disease. Aliment Pharmacol Ther 2017;46:115–125.Article PubMed PDF
32. Koning M, Ailabouni R, Gearry RB, Frampton CM, Barclay ML. Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: a population-based, case-control study. Inflamm Bowel Dis 2013;19:767–778.PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Recent Perspective of Lactobacillus in Reducing Oxidative Stress to Prevent Disease
Tingting Zhao, Haoran Wang, Zhenjiang Liu, Yang Liu, DeJi, Bin Li, Xiaodan Huang
Antioxidants.2023; 12(3): 769. CrossRef
The Role of Bitter Melon in Breast and Gynecological Cancer Prevention and Therapy
Iason Psilopatis, Kleio Vrettou, Constantinos Giaginis, Stamatios Theocharis
International Journal of Molecular Sciences.2023; 24(10): 8918. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study

Intest Res. 2022;20(2):192-202. Published online April 29, 2022

DOI: https://doi.org/10.5217/ir.2020.00150

XML Download

Figure

Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study

Fig. 1. The prevalence of complementary and alternative medicine service (A) and product (B) usage among patients with inflammatory bowel disease from 3 countries. The P-value is for the analysis of variance and was adjusted for physicians’ age and sex and the hospital type. aP<0.05, bP<0.01, cP<0.001.

Fig. 2. Comparison of physicians’ perspectives on complementary and alternative medicine (CAM) services (A) and products (B) for inflammatory bowel disease among 3 countries. The width of the box indicates the sample size of participants from each country. The P-value was calculated using the pairwise Wilcoxon rank-sum test after adjustment for physicians’ age and sex and the hospital type. aP<0.05, bP<0.001. NS, not significant.

Fig. 1.

Fig. 2.

Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study

Characteristics	China (n = 232)	Japan (n = 255)	Korea (n = 418)	P-value
Age at enrollment (yr)	38.8 ± 14.2	43.2 ± 13.7	40.8 ± 15.3	0.001
Disease duration (yr)	4.1 ± 4.4	10.8 ± 8.2	7.0 ± 6.2	< 0.001
Male sex	143 (61.6)	129 (50.6)	269 (64.5)	0.001
Comorbidities	40 (17.2)	115 (45.1)	124 (29.7)	< 0.001
SCCAI	5.1 ± 4.2	0.7 ± 1.5	1.9 ± 2.1	< 0.001
HBI score	3.8 ± 2.5	2.3 ± 2.6	2.3 ± 2.3	< 0.001
Active disease at enrollment	109 (47.0)	46 (18.0)	53 (12.7)	< 0.001
Current medications
Steroid	54 (23.3)	26 (10.2)	40 (9.6)	< 0.001
Thiopurine	45 (19.4)	106 (41.6)	135 (32.4)	< 0.001
Tacrolimus	0	8 (3.1)	0	< 0.001
Anti-TNFs	51 (22.1)	59 (23.1)	129 (30.9)	0.018
Previous surgery related with IBD	52 (22.4)	23 (9.0)	76 (18.2)	< 0.001
Previous admission related with IBD	222 (95.7)	90 (35.3)	208 (49.9)	< 0.001

Variable	China (n = 232)	Japan (n = 255)	Korea (n = 418)	Total (n = 905)	P-value^a
Massage	5 (2.2)	2 (0.8)	4 (1.0)	11 (1.2)	0.166
Acupuncture	5 (2.2)	2 (0.8)	16 (3.8)	23 (2.5)	0.995
Naturopathic medicine	4 (1.7)	1 (0.4)	1 (0.2)	6 (0.6)	0.195
Homoeopathy	2 (0.9)	0	7 (1.7)	9 (0.9)	0.898
Relaxation	6 (2.6)	2 (0.8)	2 (0.5)	10 (1.1)	0.626
Reflexology	0	4 (1.6)	5 (1.2)	9 (0.9)	0.871
Aromatherapy	0	0	0	0	NA
Hypnosis	0	0	0	0	NA
Moxibustion or cupping	8 (3.4)	0	19 (4.5)	27 (2.9)	0.051
Spiritual or religious healer	3 (1.3)	0	1 (0.2)	4 (0.4)	0.108
Chiropractic	7 (3.0)	1 (0.4)	2 (0.5)	10 (1.1)	0.047
CAM ≥ 2 services	8 (3.4)	0	14 (3.3)	22 (2.4)	0.027
Any CAM service	20 (8.6)	13 (5.1)	45 (10.8)	78 (8.6)	0.179

Variable	China (n = 232)	Japan (n = 255)	Korea (n = 418)	Total (n = 905)	P-value^a
Herbal remedies	22 (9.5)	4 (1.6)	13 (3.1)	39 (4.3)	0.002
Ginseng	1 (0.4)	0	14 (3.3)	15 (1.6)	0.814
Deer antlers	0	0	2 (0.5)	2 (0.2)	0.368
Chinese medicine (drugs)	29 (12.5)	5 (2)	33 (7.9)	67 (7.4)	< 0.001
St. John’s wort	0	0	0	0	NA
Chamomile	1 (0.4)	1 (0.4)	4 (1.0)	6 (0.6)	0.502
Lavender	0	0	1 (0.2)	1 (0.1)	0.486
Ginkgo biloba	0	0	0	0	NA
Kava kava	0	0	0	0	NA
Vitamins	70 (30.2)	2 (0.8)	36 (8.6)	108 (11.9)	< 0.001
Probiotics	81 (34.9)	19 (7.5)	75 (17.9)	175 (19.3)	< 0.001
Fish oils	1 (0.4)	3 (1.2)	5 (1.2)	9 (0.9)	0.505
Glucosamine	19 (8.2)	0	5 (1.2)	24 (2.6)	< 0.001
CAM ≥ 2 products	70 (30.2)	8 (3.1)	52 (12.4)	130 (14.3)	< 0.001
Any product	117 (50.4)	32 (12.5)	120 (28.7)	269 (29.7)	< 0.001

Factor	CAM service					CAM product
	Univariate analysis			Multivariate analysis		Univariate analysis			Multivariate analysis
	User (n=78)	Nonuser (n=827)	P-value	OR (95% CI)	P-value	User (n=269)	Nonuser (n=636)	P-value	OR (95% CI)	P-value
Age at enrollment (yr)	39.54 ± 13.43	41.09 ± 14.74	0.370			39.39 ± 13.97	41.62 ± 14.87	0.035	0.99 (0.98–1.00)	0.321
Disease duration (yr)	7.34 ± 5.86	7.29 ± 6.94	0.955			6.65 ± 6.33	7.57 ± 7.10	0.068
Male sex	46 (59.0)	495 (59.9)	0.904			158 (58.7)	383 (60.3)	0.657
Comorbidities	25 (32.1)	254 (30.7)	0.799			67 (24.9)	212 (33.3)	0.012	0.91 (0.64–1.29)	0.578
Disease			0.808					0.940
CD	31 (39.7)	314 (38)				103 (38.3)	242 (38.1)
UC	47 (60.3)	513 (62)				166 (61.7)	394 (61.9)
Countries			0.040					< 0.001
China	20 (25.6)	212 (25.6)		1.35 (0.64–2.86)	0.428	117 (43.5)	115 (18.1)		5.15 (3.10–8.58)	< 0.001
Japan	13 (16.7)	242 (29.3)		1 (reference)		32 (11.9)	223 (35.1)		1 (reference)
Korea	45 (57.7)	373 (45.1)		2.31 (1.21–4.41)	0.011	120 (44.6)	298 (46.9)		2.73 (1.77–4.22)	< 0.001
Active disease	29 (37.2)	180 (21.8)	0.003	2.46 (1.45–4.19)	0.001	87 (32.3)	122 (19.2)	< 0.001	1.45 (1.01–2.08)	0.043
Steroid	10 (12.8)	110 (13.3)	0.946			47 (17.5)	73 (11.5)	0.018	1.27 (0.83–1.96)	0.273
Thiopurine	24 (30.8)	262 (31.7)	0.899			81 (30.1)	205 (32.3)	0.533
Anti-TNFs	29 (37.2)	210 (25.5)	0.031	1.59 (0.96–2.60)	0.068	68 (25.4)	171 (26.9)	0.680
Previous surgery related with IBD	14 (18.2)	137 (16.6)	0.749			51 (19.0)	100 (15.7)	0.243
Previous admission related with IBD	47 (61.0)	473 (57.2)	0.548			192 (71.4)	328 (51.7)	< 0.001	1.28 (0.89–1.85)	0.121

Table 1. Baseline Characteristics of Patients in the Study

Values are presented as mean±standard deviation or number (%). Active disease was defined as HBI ≥5 for Crohn’s disease and SCCAI ≥5 for ulcerative colitis.

SCCAI, Simple Clinical Colitis Activity Index; HBI, Harvey-Bradshaw index; TNF, tumor necrosis factor; IBD, inflammatory bowel disease.

Table 2. Prevalence of Complementary and Alternative Medical Services Usage in Inflammatory Bowel Disease Patients According to Countries

Values are presented as number (%).

The comparison was adjusted with age, duration of disease, sex, comorbidities, disease activity, current medications and previous history of surgery and admission.

CAM, complementary and alternative medicine; NA, not applicable.

Table 3. Prevalence of Complementary and Alternative Medical Products Usage in Inflammatory Bowel Disease Patients According to Countries

Values are presented as number (%).

The comparison was adjusted with age, duration of disease, sex, comorbidities, disease activity, current medications and previous history of surgery and admission.

CAM, complementary and alternative medicine; NA, not applicable.

Table 4. Associated Factors with Complementary and Alternative Medicine in Patients with IBD

Values are presented as mean±standard deviation or number (%). Active disease was defined as Harvey-Bradshaw index ≥5 for CD and Simple Clinical Colitis Activity Index ≥5 for UC.

IBD, inflammatory bowel disease; CAM, complementary and alternative medicine; OR, odds ratio; CI, confidence interval; CD, Crohn’s disease; UC, ulcerative colitis; TNF, tumor necrosis factor.